業績

ページタイトル画像

論文業績 2011-2015

  • 2015
  • 2014
  • 2013
  • 2012
  • 2011

2015

  1. Nakaseko C, Takahashi N, Ishizawa K, Kobayashi Y, Ohashi K, Nakagawa Y, Yamamoto K, Miyamura K, Taniwaki M, Okada M, Kawaguchi T, Atsushi Shibata, Yosuke Fujii, Ono C, Ohnishi K. A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia. Int J Hematol 2015;101(2):154-164. PMID: 25540064
  2. Togasaki E, Shono K, Onoda M, Yokota A. Retrospective analysis of Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic hematopoietic stem cell transplantation versus chemotherapy combined with tyrosine kinase inhibitor. Leuk Lymphoma. 2015; 56(1): 244-247. PMID: 24730539
  3. Muto T, Sashida G, Hasegawa N, Nakaseko C, Yokote K, Shimoda K, Iwama A. MDS/MPN with massive erythroid infiltration induced by loss of Tet2 in mice. Leuk Lymphoma. 2015; 56(2):520-523. PMID: 24844363
  4. Matsushita K, Kitamura K, Rahmutulla B, Tanaka N, Ishige T, Satoh M, Hoshino T, Miyagi Y, Mori T, Itoga S, Shimada H, Tomonaga T, Kito M, Takagi-Nakajima Y, Kubo S, Nakaseko C, Hatano M, Miki T, Matsuo M, Kaneda A, Iwama A, Nomura F. Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1. Oncotarget 2015; 6(7): 5102-5117. PMID: 25671302
  5. Tanaka H, Furukawa S, Takeda Y, Shimizu N, Kawaguchi T, Kawajiri C, Hashimoto S, Takagi T, Ito S, Ota S, Kuwabara S, Nakaseko C. Primary cerebral lymphomatoid granulomatosis progressing to methotrexate-associated lymphoproliferative disease under immunosuppressive therapy. Intern Med. 2015; 54(5):503-507. PMID: 25758078
  6. Tanaka M, Kanamori H, Matsumoto K, Tachibana T, Numata A, Ohashi K, Kobayashi T, Nakaseko C, Kanda Y, Yamazaki E, Fujisawa S, Ooi J, Sakura T, Aotsuka N, Onoda M, Machida M, Kato J, Usuki K, Watanabe R, Taguchi J, Yano S, Saito T, Takahashi S, Sakamaki H, Okamoto S. Clinical significance of pretransplant serum ferritin on the outcome of allogeneic hametopoietic stem cell transplantation: a prospective cohort study by Kanto Study Group for Cell Therapy. Bone Marrow Transplant 2015; 50(5): 727-733. PMID: 25730191
  7. Muto T, Takeuchi M, Yamazaki A, Sugita Y, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Ohwada C, Sakaida E, Aotsuka N, Iseki T, Nakaseko C. Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL–positive acute myeloid leukemia. Int J Hematol. 2015; 102(1):86-92. PMID: 25758097
  8. Arai Y, Takeda J, Aoki K, Kondo T, Takahashi S, Onishi Y, Ozawa Y, Aotsuka N, Kouzai Y, Nakamae H, Ota S, Nakaseko C, Yamaguchi H, Kato K, Atsuta Y, Takami A. Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy. Blood 2015; 126(3):415-422. PMID: 26031916
  9. Kurosawa S, Yamaguchi T, Mori T, Kanamori H, Onishi Y, Emi N, Fujisawa S, Kohno A, Nakaseko C, Saito B, Kondo T, Hino M, Nawa Y, Kato S, Hashimoto A, Fukuda T. Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia. Bone Marrow Transplant 2015; 50(9):1241-1249. PMID: 26076127
  10. Yano S, Mori T, Kanda Y, Kato J, Nakaseko C, Fujisawa S, Tomita N, Sakai R, Shono K, Saitoh T, Aotsuka N, Kobayashi N, Saito T, Takahashi S, Kanamori H, Okamoto S. Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma. Bone Marrow Transplant 2015; 50(10):1299-1305. PMID: 26168068
  11. Kurimoto R, Sekine I, Iwasawa S, Sakaida E, Tada Y, Tatsumi K, Takahashi Y, Nakatani Y, Imai C, Takiguchi Y. Alveolar hemorrhage associated with pemetrexed administration. Intern Med. 2015; 54(7):833-836. PMID: 25832952
  12. Mimura N, Hideshima T, Anderson KC. Novel therapeutic strategies for multiple myeloma. Exp Hematol. 2015; 43(8):732-741. PMID: 26118499
  13. Hideshima T, Cottini F, Ohguchi H, Jakubikova J, Gorgun G, Mimura N, Tai YT, Munshi NC, Richardson PG, Anderson KC. Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma. Blood Cancer J. 2015 May 15;5:e312. PMID: 25978432
  14. Suzuki R, Hideshima T, Mimura N, Minami J, Ohguchi H, Kikuchi S, Yoshida Y, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi NC, Utsugi T, Anderson KC. Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma. Leukemia. 2015; 29(2): 510-514. PMID: 25306900
  15. Ohwada C, Yamazaki A, Kawaguchi T, Sugita Y, Takeuchi M, Shimizu N, Sakaida E, Takeda Y, Tsukamoto S, Muto T, Jiang M, Higashi M, Yokote K, Tamaru JI, Bujo H, Nakaseko C. Serum soluble LR11, a novel tumor derived biomarker associated with the outcome of patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2015; 56(10): 2982-2985. PMID: 25676033
  16. Tsukamoto S, Nagao Y, Yamazaki A, Sugita Y, Takeda Y, Muto T, Sakai S, Mimura N, Takeuchi M, Ohwada C, Sakaida E, Yokote K, Iseki T, Nakaseko C. Successful allogeneic stem cell transplantation for severe aplastic anemia after treatment of lymphoproliferative disorder caused by rabbit antithymocyte globulin. Int Med 2015; 54(24): 3197-3200. PMID: 26666612
  17. Tanaka H, Kawajiri C, Sakai S, Takeda Y, Kawaguchi T, Mimura N, Sakaida E, Ohwada C, Takeuchi M, Hashimoto S, Takagi T, Nakaseko C. Gradually-deteriorating liver function due to iron overload over four years after allogeneic stem cell transplantation. J Clin Exp Hematop. 2015; 55(2): 109-112. PMID: 26490524
  18. Mochizuki-Kashio M, Aoyama K, Sashida G, Oshima M, Tomioka T, Muto T, Wang C, Iwama A. Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-depenedent manner. Blood. 2015; 126(10): 1172-1183. PMID: 26219303
  19. Sugita Y, Ohwada C, Nagao Y, Kawajiri C, Shimizu R, Togasaki E, Yamazaki A, Muto T, Sakai S, Takeda Y, Mimura N, Takeuchi M, Sakaida E, Iseki T, Yokote K, Nakaseko C. Early-onset severe diffuse alveolar hemorrhage after bortezomib administration suggestive of pulmonary involvement of myeloma cells. J Clin Exp Hematop. 2015; 55(3): 163-168. PMID: 26763365
  20. Misawa S, Sato Y, Katayama K, Hanaoka H, Sawai S, Beppu M, Nomura F, Shibuya K, Sekiguchi Y, Mitsuma S, Iwai Y, Watanabe K, Ohwada C, Takeuchi M, Sakaida E, Nakaseko C, Kuwabara S. Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: Retrospective cohort study. BMJ Open 2015 Nov 11;5(11):e009157.　PMID: 26560063
  21. Whittle AJ, Jiang M, Peirce V, Relat J, Virtue S, Ebinuma H, Fukamachi I, Yamaguchi T, Takahashi M, Murano T, Tatsuno I, Takeuchi M, Nakaseko C, Jin W, Jin Z, Campbell M, Schneider WJ, Vidal-Puig A, Bujo H. Soluble LR11/SorLA represses thermogenesis in adipose tissue and correlates with BMI in humans. Nat Commun. 2015 Nov 20;6:8951.　PMID: 26584636
  22. Motohashi K, Fujisawa S, Onizuka M, Kako S, Sakaida E, Shono K, Tatara R, Doki N, Mori T, Sakura T, Aotsuka N, Fuji E, Tomita N, Kawai N, Saitoh T, Usuki K, Taguchi J, Watanabe R, Kobayashi S, Yano S, Kanamori H, Takahashi S, Okamoto S. Effect of the order of TBI and cyclophosphamide administration on the outcome of allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2015; 50(11):1476-9. PMID: 26191948
  23. Suzuki R, Kikuchi S, Harada T, Mimura N, Minami J, Ohguchi H, Yoshida Y, Sagawa M, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi N, Ando K, Utsugi T, Hideshima T, Anderson KC. Combination of a selective HSP90α/β inhibitor and a RAS-RAF-MEK-ERK signaling pathway inhibitor triggers synergistic cytotoxicity in multiple myeloma cells. PLoS One. 2015; 10(12):e0143847. PMID: 26630652
  24. Wang C, Oshima M, Sashida G, Tomioka T, Hasegawa N, Mochizuki-Kashio M, Nakajima-Takagi, Y, Kusunoki Y, Koizumi S, Imai K, Nakachi K, Iwama A. Non-Lethal Ionizing Radiation Promotes Aging-Like Phenotypic Changes of Human Hematopoietic Stem and Progenitor Cells in Humanized Mice. PLoS One. 2015; 10(7): e0132041. PMID: 26161905

 

和文論文

  1. 中世古知昭　今日の治療指針２０１５年版 第10章 血液疾患，顆粒球減少症（無顆粒球症）　医学書院, 東京、p671-2, 監修：山口徹，北原光夫，総編集：福井次矢，高木誠，小室一成，2015, （単行本）ISBN978-4-260-02039-8
  2. 武内正博，中世古知昭．白血病診療Q & A 一つ上を行く診療の実践. V. 慢性骨髄性白血病 (CML) 3. 初発時に付加的染色体異常を認めたCML-CPの治療は？ 編集：松村到，中外医学社，東京，p200-202, 2015 （単行本）
  3. 武内正博，中世古知昭． V. 慢性骨髄性白血病 (CML) 4. CML-CPにおける移植の位置づけは？白血病診療Q & A 一つ上を行く診療の実践. p203-206，編集：松村到，中外医学社，東京， 2015（単行本）
  4. 永尾侑平，中世古知昭. 臨床編－多発性骨髄腫と類縁疾患－　6. レナリドミド 7) POEMS症候群. IMiDs　基礎と臨床2015 p144-149，メ ディカルレビュー社，東京，2015（単行本）
  5. 川口岳晴、中世古知昭　「レナリドミド」 血液領域の分子標的療法　第3章骨髄腫，最新醫學別冊 診断と治療のABC 102 p162-168，編集：畠清彦，最新医学社，東京，2015（単行本）
  6. 中世古知昭　3. 治療　3-8. 自家末梢幹細胞移植の実際と課題.ブラッシュアップ多発性骨髄腫 p143-151, 編集：木崎昌弘，中外医学社，東京，2015　（単行本） ISBN978-4-498-12596-4
  7. 中世古知昭　Ⅱ. CMLの臨床 1. 病態診断 2) 治療効果判定. 慢性骨髄性白血病(CML)の基礎と臨床～幹細胞の特性から最新薬物療法まで～ p70-77, 編集：松村到，医薬ジャーナル社，東京，2015 ISBN978-4-7532-2766-2　（単行本）
  8. 川尻千華，中世古知昭.　5章 疾患の病因，病態，診断と治療，C. リンパ腫と骨髄腫，６. 原発性アミロイドーシス.　Principles and Practice 血液・造血器・リンパ系　医学生・レジデントのための必修エッセンス p311-317, 2015 文光堂，東京 ISBN978-4-8306-1425-5　（単行本）
  9. 中世古知昭.　What’s New in Oncology　がん治療エッセンシャルガイド　21 造血器腫瘍 急性白血病. P734-755, 編集：佐藤隆美，藤原康弘，百瀬純司，大山優, 南山堂，東京，2015（単行本）
  10. 中世古知昭. What’s New in Oncology　がん治療エッセンシャルガイド　21 造血器腫瘍 慢性骨髄性白血病　p756-768, 編集：佐藤隆美，藤原康弘，百瀬純司，大山優, 南山堂，東京，2015（単行本）
  11. 中世古知昭　特集：多発性骨髄腫をめぐる最近の進歩と話題：多発性骨髄腫に対する自家／同種造血幹細胞移植による治癒は可能か？　血液内科 2015; 70(6):710-716
  12. 竹田勇輔，堺田惠美子、中世古知昭．多発性骨髄腫の病態と最新治療．－基礎と臨床の最新情報－IV. 診断と治療研究，2. 治療，(10)レナリドミドとボルテゾミブの併用療法．日本臨牀 2015; 73(1): 130-136
  13. 清水亮，中世古知昭．特集／リンパ系腫瘍に対するさらなる新薬開発と国内外の診療 5. 慢性リンパ性白血病に対する合理的な治療選択とalemtuzumabの国内臨床導入．血液内科　2015; 71(1): 26-32
  14. 東ヶ崎絵美，大和田千桂子，中世古知昭．Ⅲ. 炎症性筋疾患―非感染性筋炎―　その他の炎症性ミオパチー　「移植片対宿主病」．別冊日本臨牀　新領域別症候群シリーズ　No. 32 骨格筋症候群（第２版）　―その他の神経筋疾患を含めて―　上　日本臨牀社，大阪，p416-420, 2015,
  15. 堺田惠美子. 特集/ICUで遭遇する血液疾患. 造血幹細胞移植に伴う肺合併症. 移植後感染性・非感染性肺合併症に対する診断と治療アプローチ. 神田善伸、林淑朗編、Intensivist. 2015; 7(2): 391-403, 2015. メディカルサイエンスインターナショナル，東京.
  16. 堺田惠美子、関根郁夫. スタンダード薬学シリーズⅡ 第6巻 第3版　薬と疾病 悪性腫瘍の病態と治療.　Ⅲ.　薬物治療(2)および薬物治療に役だつ情報　　日本薬学会編　2015年改訂
  17. 堺田惠美子.　インフォームドコンセントのための図説シリーズ. 抗悪性腫瘍薬―分子標的治療薬―改訂版 　II承認済みの分子標的治療薬　2.抗体　８）オファツムマブ：CLL、西條長宏編、医薬ジャーナル社，大阪　2015年11月
  18. 武藤朋也, 指田吾郎, 大島基彦, 岩間厚志. エピジェネティック制御遺伝子変異と骨髄系腫瘍. 臨床血液 2015; 56 (11): 2287-2294
  19. 三村尚也.　選択的Akt阻害剤による多発性骨髄腫の新規治療戦略　血液内科　2015; 71(5): 634-639.
  20. 酒井紫緒　造血幹細胞採取・細胞処理・保存　平成27年度HCTC認定講習テキスト 2015 p5-9，JSHCT monograph Vol.41 一般社団法人日本造血細胞移植学会，名古屋，2015 ISSN1344-5898 （単行本）
  21. 武藤朋也, 岩間厚志. ポリコーム群遺伝子と骨髄異形成. 医学のあゆみ 2015; 252 (9): 964-966

2014

  1. Nakaseko C. Autologous stem cell transplantation for POEMS syndrome. Clin Lymphoma Myeloma Leuk. 2014; 14(1): 21-23. PMID: 24461808
  2. Tanaka H, Ambiru S, Nakamura S, Itabashi T, Furuya S, Shimura T, Nagao Y, Kawajiri C, Takeda Y, Hashimoto S, Nakaseko C. Successful diagnosis of type II enteropathy-associated T-cell lymphoma using flow cytometry and the cell block technique of celomic fluid manifesting as massive pyoid ascites that could not be diagnosed via emergency laparotomy. Intern Med. 2014; 53(2):129-133. PMID: 24429453
  3. Fujimura K, Ebinuma H, Fukamachi I, Ohwada C, Kawaguchi T, Shimizu N, Takeuchi M, Sakaida E, Jiang M, Nakaseko C, Bujo H. Circulating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non-Hodgkin's lymphoma. Clin Chim Acta. 2014; 430: 48-54. PMID: 24394293
  4. Nasu S, Misawa S, Nakaseko C, Shibuya K, Isose S, Sekiguchi Y, Mitsuma S, Ohmori S, Iwai Y, Beppu M, Shimizu N, Ohwada C, Takeda Y, Fujimaki Y, Kuwabara S. Bortezomib-induced neuropathy: Axonal membrane depolarization precedes development of neuropathy. Clin Neurophysiol. 2014; 125(2): 381-387. PMID: 23973385
  5. Kawaguchi T, Ohwada C, Takeuchi M, Shimizu N, Sakaida E, Takeda Y, Sakai S, Tsukamoto S, Yamazaki A, Sugita Y, Higashi M, Fujikawa K, Matsue K, Yokote K, Tamaru J, Bujo H, Nakaseko C. Potential utility of serum soluble LR11 as a diagnostic biomarker for intravascular large B-cell lymphoma. Leuk Lymphoma. 2014; 55(10): 2391-2394. PMID: 24401112
  6. Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014; 123(9): 1353-1360. PMID: 24335106
  7. Tsukamoto S, Takeuchi M, Kawaguchi T, Togasaki E, Yamazaki A, Sugita S, Muto T, Sakai S, Takeda Y, Ohwada C, Sakaida E, Shimizu N, Nishii K, Jiang M, Yokote K, Bujo H, Nakaseko C. Tetraspanin CD9 modulates ADAM17-mediated shedding of LR11 in leukocytes. Exp Mol Med. 2014 Apr 4 46:e89, PMID: 24699135
  8. Isshiki Y, Ohwada C, Togasaki E, Shimizu R, Hasegawa N, Yamazaki A, Sugita Y, Kawaguchi T, Tsukamoto S, Sakai S, Takeda Y, Takeuchi M, Sakaida E, Shimizu N, Ota S, Yokote K, Iseki T, Nakaseko C. Acute myeloid leukemia concurrent with spinal epidural extramedullary myeloid sarcoma accompanied by high CD25 expression and FLT3-ITD mutation. Intern Med. 2014; 53(11):1159-1164. PMID: 24881741
  9. Kihara R, Nagata Y, Kiyoi H, Kato T, Yamamoto E, Suzuki K, Chen F, Asou N, Ohtake S,  Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Kiguchi T, Imai K, Uike N, Kimura F, Kitamura K, Nakaseko C, Onizuka M, Takeshita A, Ishida F, Suzushima H, Kato Y, Miwa H, Ogawa S, Naoe T. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients treated with the Japan Adult Leukemia Study Group (JALSG) AML201 study. Leukemia. 2014; 28(8):1586-1595 PMID: 24487413
  10. Kawajiri C, Tanaka H, Hashimoto H, Takeda Y, Sakai S, Takagi T, Takeuchi M, Ohwada C, Sakaida E, Shimizu N, Nakaseko C. Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status. Int J Hematol. 2014; 99(4):513-518, PMID: 24532437
  11. Shimizu N, Nakaseko C, Jiang M, Nishii K, Ohwada C, Takeuchi M, Yokote K, Iseki T, Higashi M, Tamaru J, Schneider WJ, Bujo H. G-CSF induces the release of the soluble form of LR11, a regulator of myeloid cell mobilization in bone marrow. Ann Hematol. 2014; 93(7):1111-1122. PMID: 24577511
  12. Murata M, Nishida T, Taniguchi S, Ohashi K, Ogawa H, Fukuda T, Mori T, Kobayashi H, Nakaseko C, Yamagata N, Morishima Y, Nagamura-Inoue T, Sakamaki H, Atsuta Y, Suzuki R, Naoe T. Allogeneic transplantation for primary myelofibrosis with bone marrow, peripheral blood, or umbilical cord blood: An analysis of the JSHCT. Bone Marrow Transplant. 2014; 49(3): 355-360. PMID: 24270391
  13. Ono T, Takeshita A,Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, Emi N, Horikawa K, Matsuda M, Shinagawa K, Monma F, Ohtake S, Nakaseko C, Takahashi M, Kimura Y, Iwanaga M, Asou N, Naoe T. CD56 expression is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts. Cancer Sci. 2014; 105(1): 97-104. PMID: 24206578
  14. Sakaida E, Sekine I, Iwasawa S, Kurimoto R, Uehara T, Ooka Y, Akanuma N, Tada Y, Imai C, Oku T, Takiguchi Y. Incidence, risk factors and treatment outcomes of extravasation of cytotoxic agents in an outpatient chemotherapy clinic. Jpn J Clin Oncol. 2014; 44(2): 168-171. PMID: 24302758
  15. Hideshima T, Mazitschek R, Santo L, Mimura N, Gorgun G, Richardson PG, Raje N, Anderson KC. Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors. Leukemia. 2014; 28(2): 457-460. PMID: 24150220
  16. Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, Cirstea D, Hu Y, Mimura N, Ohguchi H, Cottini F, Jakubikova J, Munshi NC, Haggarty SJ, Richardson PG, Hideshima T, Anderson KC. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia. 2014; 28(3): 680-689. PMID: 23913134
  17. Nakaya A, Mori T, Tanaka M, Tomita N, Nakaseko C, Yano S, Fujisawa S, Sakamaki H, Aotsuka N, Yokota A, Kanda Y, Sakura T, Nanya Y, Saitoh T, Kanamori H, Takahashi S, Okamoto S. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplant outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy (KSGCT). Biol Blood Marrow Transplant. 2014; 20(10): 1553-1559, PMID: 25034961
  18. Mimura N, Hideshima T, Shimomura T, Suzuki R, Ohguchi H, Rizq O, Kikuchi S, Yoshida Y, Cottini F, Jakubikova J, Cirstea D, Gorgun G, Minami J, Tai YT, Richardson PG, Utsugi T, Iwama A, Anderson KC. Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. Cancer Res. 2014; 74(16):4458-4469. PMID: 24934808
  19. Sashida G, Harada H, Matsui H, Oshima M, Yui M, Harada Y, Tanaka S, Mochizuki-Kashio M, Wang C, Saraya A, Muto T, Hayashi Y, Suzuki K, Nakajima H, Inaba T, Koseki H, Huang G, Kitamura T, Iwama A. Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation. Nat Commun. 2014 Jun 23;5:4177. PMID: 24953053
  20. Takiguchi Y, Sekine I, Iwasawa S, Kurimoto R, Sakaida E, Tamura K. Current Status of Medical Oncology in Japan—Reality Gleaned from a Questionnaire Sent to Designated Cancer Care Hospitals. Jpn J Clin Oncol. 2014; 44(7): 632-640. PMID: 24821975
  21. Aoki T, Izutsu K, Suzuki R, Nakaseko C, Arima H, Shimada K, Sasaki M, Takizawa J, Mitani K, Igarashi T, Maeda Y, Fukuhara N, Ishida F, Niitsu N, Ohmachi K, Takasaki H, Nakamura N, Kinoshita T, Nakamura S, Ogura M. Prognostic significance of pleural or pericardial effusion, and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan. Haematologica. 2014; 99(12):1817-1825. PMID: 25216682
  22. Nakamoto S, Kanda T, Nakaseko C, Sakaida E, Ohwada C, Takeuchi M, Takeda Y, Mimura N, Iseki T, Wu E, Arai M, Imazeki F, Saito K, Shirasawa H, Yokosuka O. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment. Int J Mol Sci. 2014; 15(11): 21455-21467. PMID: 25421241
  23. Jin H, Mimura N, Kashio M, Koseki H, Aoe T. Late-onset of spinal neurodegeneration in knock-in mice expressing a mutant BiP. PLoS One. 2014 Nov 18;9(11):e112837. PMID: 25405877
  24. Togasaki-Yoshimoto E, Shono K, Onoda M, Yokota A. The occurrence of second neoplasms after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia. Leuk Lymphoma. 2014 Feb;55(2):453-6. PMID: 23697842

 

和文論文

  1. 武藤朋也，中世古知昭. Alemtuzumabの抗腫瘍スペクトラムと使用上の注意　特集「血液腫瘍に対する抗体医薬のさらなる進展」　血液内科　2014; 68(4): 448-454.
  2. 竹田勇輔，中世古知昭. 血液疾患患者に薬剤を使うとき. 特集：もう見逃さない！迷わない！　非血液専門医のための血液診療　medicina 2014; 51(3):505-509
  3. 中世古知昭　　第4章　管理・治療　自家移植療法　最新医学別冊　新しい診断と治療のABC 84 血液10 多発性骨髄腫　編集：畠清彦，最新医学社 p156-165, 2014, ISSN 0370-8241
  4. 中世古知昭　多発性骨髄腫Updating 第4巻　移植適応骨髄腫の治療 Ⅲ.自家末梢血幹細胞移植　4. 末梢血幹細胞採取，3) Plerixafor　編集：清水一之，医薬ジャーナル社，大阪，p92-96, 2014, ISBN978-4-7532-2644-3（単行本）
  5. 中世古知昭　多発性骨髄腫Updating 第4巻　移植適応骨髄腫の治療　V.同種造血幹細胞移植の今後の展望～ハイリスク症例，形質細胞白血病に対する移植～　編集：清水一之，医薬ジャーナル社，大阪，p184-191, 2014, ISBN978-4-7532-2644-3（単行本）
  6. 中世古知昭　多発性骨髄腫Updating 第4巻　移植適応骨髄腫の治療　V.同種造血幹細胞移植の今後の展望　ここに注目！　同種移植後の新規薬剤とGVHD　編集：清水一之，医薬ジャーナル社，大阪，p192-196, 2014, ISBN978-4-7532-2644-3（単行本）
  7. 中世古知昭　特集：多発性骨髄腫と類縁疾患　10. POEMS症候群の病態と治療　血液内科 2014 69(4):508-514
  8. 中世古知昭　多発性骨髄腫Updating第6巻　ALアミロイドーシス，多発性骨髄腫の類縁疾患. II. POEMS症候群　2. 診断・診断基準　ALアミロイドーシス，多発性骨髄腫の類縁疾患　p187-195, 編集：清水一之，医薬ジャーナル社，東京，2014（共著）ISBN978-4-7532-2684-9（単行本）
  9. 中世古知昭　多発性骨髄腫Updating第6巻　ALアミロイドーシス，多発性骨髄腫の類縁疾患. II. POEMS症候群　3. 治療～化学療法・移植療法・新規薬剤を含む～　ALアミロイドーシス，多発性骨髄腫の類縁疾患　p196-205, 編集：清水一之，医薬ジャーナル社，東京，2014（共著）ISBN978-4-7532-2684-9（単行本）
  10. 中世古知昭　EBM血液疾患の治療　2015-2016 骨髄腫類縁疾患（Castleman病，POEMS症候群）の治療　編集：金倉譲，木崎昌弘，鈴木律郎，神田善伸，中外医学社、東京、p401-406, 2014, ISBN978-4-498-12582-7（単行本）
  11. 宮村耕一、岡本真一郎、薄井紀子、日野雅之、赤司浩一、中世古知昭、高橋直人、中谷中、高橋 啓太，登勉、直江知樹. キャリブレーターによる国際標準値変換を可能とするMajor BCR-ABL mRNA測定キットの臨床性能評価. 臨床血液 2014; 55(5): 534-40. PMID: 24881918
  12. 中世古知昭　自家移植適応骨髄腫の治療．臨床血液 55(10): 308-318, 2014
  13. 堺田惠美子　診療科・基礎疾患から見た大切な真菌症　血液内科. 目で見る真菌と真菌症  編集：亀井克彦. 医薬ジャーナル社, 大阪, p84-93,2014, ISBN978-4-7532-2678-8 C3047（単行本）
  14. 長谷川渚、指田吾郎、岩間厚志．造血器悪性腫瘍におけるエピゲノム異常　特集「白血病幹細胞」　血液フロンティア　2014; 24(12): 1755-1762
  15. 大西一功，木村晋也，中世古知昭．慢性骨髄性白血病の分子標的治療における新戦略－安全性プロファイルの違いから考える－　Leukemia Insight 2014; 1: 2-5

2013

  1. Kawaguchi T, Takeuchi M, Kawajiri C, Abe D, Nagao Y, Yamazaki A, Sugita Y, Tsukamoto S, Sakai S, Takeda Y, Ohwada C, Sakaida E, Shimizu N, Yokote K, Iseki T, Nakaseko C. Severe hyponatremia caused by syndrome of inappropriate secretion of antidiuretic hormone developed as initial manifestation of human herpesvirus-6 associated acute limbic encephalitis after unrelated bone marrow transplantation. Transpl Infect Dis. 2013; 15(2):E54-57, PMID:23173742
  2. Nishii K, Nakaseko C, Jiang M, Shimizu N, Takeuchi M, Schneider WJ, Bujo H. The soluble form of LR11 is a regulator of hypoxia-induced, uPAR-mediated adhesion of immature hematological cells. J Biol Chem. 2013;288(17):11877-11886, PMID:23486467
  3. Tanaka H, Shimizu N, Tougasaki E, Kawajiri C, Hashimoto S, Takeda Y, Sakai S, Takeuchi M, Ohwada C, Sakaida E, Takagi T, Nakaseko C. Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome. Int J Hematol. 2013; 97(4): 520-524, PMID:23519573
  4. Oshima K, Kanda Y, Nanya Y, Tanaka M, Nakaseko C, Yano S, Fujisawa S, Fujita H, Yokota A, Takahashi S, Kanamori H, Okamoto S for the Kanto Study Group for Cell Therapy (KSGCT). Allogeneic hematopoietic stem cell transplantation for patients with mildly reduced renal function as defined based on creatinine clearance before transplantation. Ann Hematol. 2013; 92(2):255-260. PMID:23053182
  5. Mori T, Tanaka M, Kobayashi T, Ohashi K, Fujisawa S, Yokota A, Fujita H, Nakaseko C, Sakura T, Nannya Y, Takahashi S, Kanamori H, Sakamaki H, Okamoto S for the Kanto Study Group for Cell Therapy (KSGCT). Prospective multicenter study of single-unit cord blood transplantation with myeloablative conditioning for adult patients with high-risk hematological malignancies. Biol Blood Marrow Transplant. 2013;19(3):486-489　PMID:23253560
  6. Yamada Y, Sawai S, Misawa S, Kanai K, Shibuya K, Mori M, Moriya J, Sogawa K, Yamamoto H, Beppu M, Taniguchi J, Nakaseko C, Nomura F, Kuwabara S. Multiple angiogenetic factors are upregulated in POEMS syndrome. Ann Hematol. 2013; 92(2):245-248. PMID: 23053181.
  7. Sekiguchi Y, Misawa S, Shibuya K, Nasu S, Mitsuma S, Iwai Y, Beppu M, Sawai S, Ito S, Hirano S, Nakaseko C, Kuwabara S. Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome. J Neurol Neurosurg Psychiatry. 2013; 84(12):1346-1348, PMID:23463868
  8. Takamatsu H, Ogawa Y, Kobayashi N, Obata K, Narisawa T, Nakayama K, Munemoto S, Aoki G, Ohata K, Kumano Y, Ozaki J, Murata R, Kondo Y, Terasaki Y, Miyamoto T, Shimizu N, Fukushima T, Yoshida A, Ueda T, Yoshida T, Nakao S. Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides. Exp Hematol. 2013; 41(10): 894-902. PMID: 23727584
  9. Kawaguchi T, Ohwada C, Takeuchi M, Shimizu N, Sakaida E, Takeda Y, Sakai S, Tsukamoto S, Yamazaki A, Sugita Y, Jiang M, Higashi M, Yokote K, Tamaru J, Bujo H, Nakaseko C. LR11: a novel biomarker identified in follicular lymphoma. Brit J Haematol. 2013; 163(2): 277-280. PMID: 23848957
  10. Tsukamoto S, Nakaseko C, Takeuchi M, Kumagai K, Komatsu T, Tanaka H, Hara S, Koizumi M, Imai H, Yokota A, Takeuchi M, Inokuchi K, Matsuura Y, Aotsuka N, Wakita H. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia. Brit J Haematol. 2013; 163(2): 286-289. PMID: 23862773
  11. Tsukamoto S, Ota S, Ohwada C, Takeda Y, Takeuchi M, Sakaida E, Shimizu N, Yokote K, Iseki T, Nakaseko C. Extramedullary blast crisis of chronic myeloid leukemia as an initial presentation. Leuk Res Rep. 2013; 2(2): 67–69. PMID: 24371785
  12. Fujita H, Asou N, Iwanaga M, Hyo R, Nomura S, Kiyoi H, Okada M, Inaguma Y, Matsuda M, Yamauchi T, Ohtake S, Izumi T, Nakaseko C, Ishigatsubo Y, Shinagawa K, Takeshita A, Miyazaki Y, Ohnishi K, Miyawaki S, Naoe T. Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97. Cancer Sci. 2013; 104(10): 1339-1345. PMID: 23837667
  13. Tanaka H, Yoshino K, Sakaida E, Sugita S, Hashimoto S, Takeda Y, Sakai S, Takagi T, Nakaseko C. Secondary neurolymphomatosis detected by whole-body diffusion-weighted magnetic resonance imaging. J Clin Exp Hematop. 2013; 53(3): 221-226. PMID: 24369224
  14. Muto T, Sashida G, Oshima M, Wendt GR, Mochizuki-Kashio M, Miyagi S, Nagae E, Sanada M, Nakaseko C, Yokote K, Shimoda K, Koseki H, Suzuki Y, Sugano S, Aburatani H, Ogawa S, Iwama A. Concurrent depletion of Ezh2 and Tet2 propagates epigenomic alterations and accelerates development of myelodysplastic disorders in mice. J Exp Med. 2013; 210(12): 2627-2639. PMID: 24218139
  15. Shimomura I, Tada Y, Miura G, Suzuki T, Matsumura T, Tsushima K, Terada J, Kurimoto R, Sakaida E, Sekine I, Takiguchi Y, Yamamoto S, Tatsumi K. Choroidal metastasis of non-small cell lung cancer that responded to gefitinib. Case Rep Ophthalmol Med. 2013; 2013: 213124, PMID: 24109538
  16. Kitazono S, Takiguchi Y, Ashinuma H, Saito-Kitazono M, Kitamura A, Chiba T, Sakaida E, Sekine I, Tada Y, Kurosu K, Sakao S, Tanabe N, Iwama A, Yokosuka O, Tatsumi K. Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. Int J Oncol. 2013; 43(6):1846-1854. PMID: 24100792

 

和文論文

  1. 中世古知昭. 解説：POEMS症候群症候群に対する自家移植　血液内科 2013; 66(6): 789-797.
  2. 中世古知昭. 私の選んだ重要論文．日本造血細胞移植学会ニュースレター 2013 No.50, p15
  3. 宮本仁，鈴木貴明，山崎伸吾，今井千晶，古賀ひとみ，竹田真理子，仲佐啓詳，中村裕義，有吉範高，中世古知昭，北田光一．造血幹細胞移植後のシクロスポリンによる腎障害の危険因子の解析．医療薬学　2013; 39(1): 45-51
  4. 中世古知昭.　みんなに役立つGVHD（移植片対宿主病）の基礎と臨床. Ⅲ. 臨床編：予防・治療 8. 肺GVHDの診断・治療.編集：豊嶋崇徳，医薬ジャーナル社，東京,　2013 p284-293（単行本）
  5. 中世古知昭.　多発性骨髄腫Updating 第4巻：移植適応骨髄腫の治療 ～新規薬剤の時代における移植適応患者の治療戦略～ 3. 自家造血幹細胞移植 4)末梢血幹細胞採取 ③Plerixafor.　編集：清水一之，医薬ジャーナル社，東京, 2013 p92-96（単行本）
  6. 中世古知昭.　多発性骨髄腫Updating 第4巻：移植適応骨髄腫の治療 ～新規薬剤の時代における移植適応患者の治療戦略～5. 同種造血幹細胞移植の今後の展望 ～ハイリスク症例，形質細胞性白血病に対する移植～ 編集：清水一之，医薬ジャーナル社，東京, 2013 p184-191（単行本）
  7. 中世古知昭. 多発性骨髄腫Updating 第4巻：移植適応骨髄腫の治療 ～新規薬剤の時代における移植適応患者の治療戦略～ ここに注目：同種移植後の新規薬剤とGVHD. 編集：清水一之，医薬ジャーナル社，東京, 2013 p192-196（単行本）
  8. 中世古知昭. 特集；リンパ性白血病診療の現状と展望. 成人球性リンパ性白血病に対する造血幹細胞移植：現状と展望．血液内科 2013; 66(2): 188-196
  9. 中世古知昭，福田隆浩，Mohamad Mohty, Chistopher Bredeson, 神田喜伸. 世界における造血幹細胞移植前治療の現状. Medicament News, 2013年9月25日号
  10. 堺田惠美子、滝口裕一，骨転移の管理．日本臨牀　最新肺癌学　基礎と臨床の最新研究動向. 2013年11月増刊号
  11. 堺田惠美子、滝口裕一、透析患者に対する肺がんの薬物療法. ガイドラインには載っていない肺がんPractical Treatment  メジカルビュー社
  12. 中世古知昭　カラーテキスト血液病学　第２版 第8章　造血器腫瘍と関連疾患　H. 多発性骨髄腫と類縁疾患： POEMS症候群（Crow-Fukase症候群、高月病）　　木崎昌弘編著　p582-585, 2013 ISBN978-4-498-12539-1（単行本）
  13. 武藤朋也　岩間厚志．白血病幹細胞におけるエピジェネティック制御　特集「血液疾患におけるエピゲノム異常と治療」　血液内科　2013; 66(3): 274-282
  14. 武藤朋也, 岩間厚志. 血液癌幹細胞エピゲノム. 2013 Medical Science Digest 39: p408-411

2012

  1. Tanaka H, Ohwada C, Hashimoto S, Sakai S, Takeda Y, Abe D, Takagi T, Ohshima K, Nakaseko C. Leukemic presentation of ALK-negative anaplastic large cell lymphoma in a patient with myelodysplastic syndrome. Intern Med. 2012; 51(2): 199-203. PMID: 22246491
  2. Yokota A, Ozawa S, Tsuji M, Akiyama H, Ohshima K, Kanda Y, Takahashi S, Mori T, Nakaseko C, Onoda M, Kishi K, Doki N, Aotsuka N, Kanamori H, MarutaA, Sakamaki H, Okamoto S for the Kanto Study Group for Cell Therapy. Secondary solid tumors after allogeneic stem cell transplantation in Japan. Bone Marrow Transplant. 2012; 47(1): 95-100. PMID: 21358690
  3. Tsukamoto S, Takeuchi M, Kawajiri C, Tanaka S, Nagao Y, Sugita Y, Yamazaki A, Kawaguchi T, Muto T, Sakai S, Takeda Y, Ohwada C, Sakaida E, Shimizu N, Yokote K, Iseki T, Nakaseko C. Posterior reversible encephalopathy syndrome in an adult patient with acute lymphoblastic leukemia after remission induction chemotherapy. Int J Hematol. 2012; 95(2): 204–208. PMID: 22160836
  4. Usuki K, Tojo A, Maeda Y, Kobayashi Y, Matsuda A, Ohyashiki K, Nakaseko C, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Okamoto S, Oritani K, Okada M, Usui N, Nagai T, Amagasaki T, Wanajo A, Naoe T. Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study. Int J Hematol. 2012; 95(4): 409-419. PMID: 22359103
  5. Ohnishi K, Nakaseko C, Takeuchi J, Fujisawa S, Nagai T, Yamazaki H, Tauchi T, Imai K, Mori N, Yagasaki F, Akiyama H, Maeda Y, Usui N, Saburi Y, Ishida T, Kosugi H, Miyamura K, Miyazaki Y, Handa H, Yokota A, Matsumoto K, Fujimaki K, Matsui T, Kiyoi H, Miyawaki S, Ohtake S, Ohno R, Naoe T, for the Japan Adult Leukemia Study Group (JALSG).　Excellent long-term outcomes of imatinib therapy in newly diagnosed Japanese patients with chronic myelogenous leukemia in chronic phase: Analysis of the mean daily doses and blood levels of imatinib in the JALSG CML202 study. Cancer Sci.2012; 103(6): 1071-1078. PMID: 22364419
  6. Takeuchi M, Nakaseko C, Ohwada C, Sato Y, Ohashi K, Kakihana K, Mori T, Aisa Y, Kanda Y, Takahashi S, Yokota A, Kawaguchi T, Saitoh T, Hatsumi N, Taguchi J, Takasaki H, Kanamori H, Maruta A, Sakamaki H, and Okamoto S. Allogeneic hematopoietic stem cell transplantation for primary and secondary myelofibrosis: a retrospective, multicenter study of the Kanto Study Group for Cell Therapy (KSGCT). J Hematopoietic Cell Transplant. 2012; 1(1): 15-23.
  7. Kanai K, Sawai S, Sogawa K, Mori M, Misawa S, Shibuya K, Isose S, Fujimaki Y, Sekiguchi Y, Nasu S, Nakaseko C, Takano S, Yoshitomi H, Miyazaki M, Nomura F, Kuwabara S. Markedly upregulated interleukin-12 as a novel biomarker in POEMS syndrome. Neurology. 2012; 79(6): 575-582. PMID:22843279
  8. Sazuka S, Takahashi Y, Kawaguchi T, Sato T, Nakagawa T, Furuya Y, Saito M, Saito K, Katsuno T, Nakaseko C, Yokosuka O. Endoscopic findings of small-intestinal Epstein-Barr virus-associated T-cell lymphoproliferative disorder. Endoscopy. 2012; 44(S 02): E30-E31. PMID:22396263
  9. Shimizu N, Nakaseko C, Sakaida E, Ohwada C, Takeuchi M, Tanaka S, Muto T, Kawaguchi T, Tsukamoto S, Sakai S, Takeda Y, Abe D, Yokote K, Iseki T, Kanai K, Misawa S, Kuwabara S. Factors associated with the efficiency of peripheral blood stem cell harvest in patients with POEMS syndrome undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2012; 47 (7): 1010-1012. PMID: 22041850
  10. Shimizu N, Sakaida E, Ohwada C, Takeuchi M, Kawaguchi T, Tsukamoto S, Sakai S, Takeda Y, Sugita Y, Yokote K, Iseki T, Isose S, Kanai K, Misawa S, Kuwabara S, Nakaseko C. Mobilization of peripheral blood stem cells in poor mobilizers with POEMS syndrome using G-CSF with plerixafor. Bone Marrow Transplant. 2012; 47(12):1587-1588. PMID:22609884
  11. Tanaka S, Miyagi S, Sashida G, Chiba T, Yuan J, Mochizuki-Kashio M, Suzuki Y, Sugano S, Nakaseko C, Yokote K, Koseki H, Iwama A. Ezh2 augments leukemogenecity by reinforcing differentiation blockage in acute myeloid leukemia. Blood. 2012; 120(5): 1107-1117. PMID:22677129
  12. Shimizu H, Saitoh T, Tanaka M, Mori T, Sakura T, Kawai N, Kanda Y, Nakaseko C, Yano S, Fujita H, Fujisawa S, Miyawaki S, Kanamori H, Okamoto S. Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma. Leukemia. 2012; 26(12): 2469-2673. PMID 22699453
  13. Tanaka H, Sakuma I, Hashimoto S, Takeda Y, Sakai S, Takagi T, Shimura T, Nakaseko C. Hepatitis B Reactivation in a Multiple Myeloma Patient with Resolved Hepatitis B Infection during Bortezomib Therapy : Case Report.　J Clin Exp Hematop. 2012; 52(1): 67-69. PMID: 22706534
  14. Kuwabara S, Dispenzieri A, Arimura K, Misawa S, Nakaseko C. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev. 2012 Jun 13; 6: CD006828. PMID: 22696361
  15. Sakai S, Nakaseko C, Takeuchi M, Ohwada C, Shimizu N, Tsukamoto S, Kawaguchi T, Jiang M, Sato Y, Ebinuma H, Yokote K, Iwama A, Fukamachi I, Schneider WJ, Saito Y, Bujo H. Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias. Clin Chim Acta. 2012; 413(19-20):1542-1548. PMID: 22750733
  16. Tanaka H, Hashimoto S, Sugita Y, Sakai S, Takeda Y, Abe D, Takagi T, Nakaseko C. Occurrence of lymphoplasmacytic lymphoma 6 years after amelioration of primary cold agglutinin disease by rituximab therapy. Int J Hematol. 2012; 96(4):501-5. PMID: 22878940.
  17. Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, Tsuzuki M, Horikawa K, Matsuda M, Shinagawa K, Monma F, Ohtake S, Nakaseko C, Takahashi M, Kimura Y, Iwanaga M, Asou N, Naoe T; Japan Adult Leukemia Study Group. Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia. Cancer Sci. 2012; 103(11):1974-1978. PMID:22834728
  18. Ashinuma H, Takiguchi Y, Kitazono S, Kitazono-Saitoh M, Kitamura A, Chiba T, Tada Y, Kurosu K, Sakaida E, Sekine I, Tanabe N, Iwama A, Yokosuka O, Tatsumi K. Antiproliferative action of metformin in human lung cancer cell lines. Oncol Rep. 2012; 28(1):8-14.
  19. Kitazono-Saitoh M, Takiguchi Y, Kitazono S, Ashinuma H, Kitamura A, Tada Y, Kurosu K, Sakaida E, Sekine I, Tanabe N, Tagawa M, Tatsumi K. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines. Oncol Rep. 2012; 28(1): 33-40

 

和文論文

  1. 中世古知昭. What’s New in Oncology がん治療エッセンシャルガイド　 各論21. 白血病：急性骨髄性白血病. p671-691,編集：佐藤隆美，藤原康弘，百瀬純司，大山優, 南山堂，東京，2012. （単行本） ISBN:978-4-525-42022-2
  2. 中世古知昭. What’s New in Oncology がん治療エッセンシャルガイド各論21. 白血病：慢性骨髄性白血病. p691-702,編集：佐藤隆美，藤原康弘，百瀬純司，大山優, 南山堂，東京，2012. （単行本）ISBN:978-4-525-42022-2
  3. 中世古知昭. 多発性骨髄腫の診療指針 第3版. 研究的治療－同種移植（ミニ移植含む）. p60-62, 日本骨髄腫学会編，文光堂，東京，2012（単行本）
  4. 中世古知昭. 多発性骨髄腫の診療指針 第3版.　V 類縁疾患　POEMS症候群（crow-Fukase症候群，高月病）に対する治療方針.　 p74-76, 日本骨髄腫学会編文光堂，東京，2012（単行本）
  5. 中世古知昭. EBM 血液疾患の治療2013-2014 IV. 多発性骨髄腫と関連疾患. 5. 多発性骨髄腫に対する同種造血幹細胞移植の可能性., p394-399，編集：金倉譲，木崎昌弘，鈴木律朗，神田善伸，中外医学社，東京，2012. ISBN 978-4-498-12576-6（単行本）
  6. 中世古知昭. ＩＩ．臨床編 b 移植合併症　9.非感染性呼吸器合併症 みんなに役立つ造血幹細胞移植の基礎と臨床改訂 神田善伸編　医薬ジャーナル社，大阪，2012; p466-473（単行本）
  7. 清水直美、中世古知昭. POEMS症候群の病態と骨髄病変. 血液内科 2012; 64(6): 747-755
  8. 堺田恵美子、滝口裕一. 肥大性骨関節症　呼吸 2012; 31(1):45-49
  9. 大和田千桂子、井関徹.　 New 専門医を目指すケース・メソッド・アプローチ　血液疾患　第二版. Case 34.　発熱、咳から汎血球減少が判明した55歳男性. 日本医事新報社, 東京, 2012, p355-361. （単行本）
  10. 中世古知昭、高橋直人、前田嘉信，神田喜伸　フィラデルフィア染色体陽性急性リンパ性白血病に対する新たな治療戦略　Hematology Today 特別企画 2012, p2-8 in press
  11. 及川真喜子、神戸直智、川口岳晴、中世古知昭、松江弘之.　ランダム皮膚生検により診断したintravascular large B-cell lymphomaの1例　皮膚科の臨床 2012; 54(7):
  12. 中世古知昭　特集：リポ蛋白受容体－細胞機能から病態解明へ. 白血病幹細胞と可溶型受容体.　Lipids 2012; 23 (4): 93-100.
  13. 中世古知昭. 第5土曜特集 POEMS症候群に対する新規薬剤と自家末梢血幹細胞移植による集学的治療. 医学のあゆみ 2012; 242(13): 1091-1097
  14. 堺田恵美子、関根郁夫. スタンダード薬学シリーズ 第6巻 薬と疾病Ⅲ. 薬物治療および薬物治療に役だつ情報　第2版　in press
  15. 堺田恵美子. 目で見る真菌と真菌症　基礎疾患から見た大切な真菌症(血液内科). 化学療法の領域　2012; 28(9): 1795-1804
  16. 中世古知昭　多発性骨髄腫治療マニュアル　Ⅲ. 多発性骨髄腫の治療手段. C. 多発性骨髄腫に対する造血幹細胞移植療法南江堂，2012 p120-135（単行本）

2011

  1. Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, Nagai T, Ohnishi K, Maeda Y, Matsuda A, Amagasaki T, Yanada M, for the Japanese AMN107/2303 Study Group. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. Int J Hematol. 2011; 93(5):624-632. PMID:21523338
  2. Usui N, Takeshita A, Nakaseko C, Ohwada C, Dobashi N, Fujita H, Kiyoi H, Kobayashi Y, Miyazaki Y, Ohtake S, Miyawaki S, Ohno R, Naoe T, Ohnishi K.　Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult AML -JALSG-AML206 study.　Cancer Sci. 2011; 102(7):1358-1365. PMID: 21585619
  3. Arai A, Imadome KI, Watanabe Y, Takahashi M, Kawaguchi T, Nakaseko C, Fujiwara S, Miura O. Clinical features and effect of chemotherapy of chronic active Epstein-Barr virus infection in adulthood, a retrospective analysis. Int J Hematol. 2011; 93(5): 602-609. PMID: 21491104
  4. Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Masuya M, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, and Ohno R. Randomized Study of Induction Therapy Comparing Standard-dose Idarubicin with High-dose Daunorubicin in Adult Patients with Previously Untreated Acute Myeloid Leukemia: JALSG AML201 Study. Blood. 2011; 117(8): 2358-2365. PMID: 20693429
  5. Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T, Miyamura K, Nakaseko C, Miyazaki Y,Masuya M, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, and Ohno R. A Randomized Comparison of Four Courses of Standard-Dose Multiagent Chemotherapy versus Three Courses of High-Dose Cytarabine alone in Post-remission Therapy for Acute Myeloid Leukemia in Adults: the JALSG AML201 Study. Blood. 2011 117(8): 2366-2372. PMID: 21190996
  6. Nakaseko C, Ozawa S, Sakaida E, Sakai M, Kanda Y, Oshima K, Kurokawa M, Takahashi S, Ooi J, Shimizu T, Yokota A, Yoshiba F, Fujimaki K, Kanamori H, Sakai R, Saitoh T, Sakura T, Maruta A, Sakamaki H and Okamoto S. Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. Int J Hematol. 2011; 93(3): 375-382. PMID: 21424350
  7. Sakai R, Kanamori H, Nakaseko C, Yoshiba F, Fujimaki K, Sakura T, Fujisawa S, Kawai N, Onoda M, Matsushima T, Maruta A, Sakamaki H, Okamoto S. Air-leak syndrome following allo-SCT in adult patients: report from the Kanto Study Group for Cell Therapy in Japan. Bone Marrow Transplant. 2011; 46(3):379-384. PMID: 20577219
  8. Takeda Y, Nakaseko C, Tanaka H, Takeuchi M, Yui M, Saraya A, Miyagi S, Ohwada C, Sakaida E, Yamaguchi N, Yokote K, Hennighausen L, Iwama A. Direct activation of Stat5 by TEL-Lyn fusion protein promotes induction of myeloproliferative disease with myelofibrosis. Brit J Haematol. 2011; 153(5):589-598. PMID: 21492125
  9. Isose S, Misawa S, Kanai K, Shibuya K, Sekiguchi Y, Nasu S, Fujimaki Y, Noto Y, Nakaseko C, Kuwabara S. POEMS syndrome with Guillan-Barr, syndrome-like acute onset: A case report and review of neurological progression in 30 cases. J Neurol Neurosurg Psychiatry. 2011; 82(6): 678-680. PMID:20562460
  10. Yamasaki K‚ Horiguchi S‚ Kurosaki M‚ Kunii N‚ Nagato K‚ Hanaoka H‚ Shimizu N‚ Ueno N‚ Yamamoto S‚ Taniguchi M‚ Motohashi S‚ Nakayama T‚ Okamoto Y. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol. 2011; 138(3): 255-265. PMID: 21185787
  11. Tanaka H, Hashimoto S, Abe D, Sakai S, Takagi T. Double-Hit Lymphoma at Second Relapse of Burkitt-Like Lymphoma : A Case Report. J Clin Exp Hematopathol. 2011; 51 (1): 43-47. PMID: 21628860
  12. Shibuya K, Misawa S, Horikoshi T, Kanai K, Isose S, Nasu S, Sekiguchi Y, Noto Y, Fujimaki Y, Nakaseko C, Kuwabara S. Detection of Bone Lesions by CT in POEMS Syndrome. Intern Med. 2011; 50(13): 1393-1396. PMID: 21720058
  13. Ohwada C, Takeuchi M, Kawaguchi T, Tsukamoto S, Muto T, Tanaka S, Sakai S, Takeda Y, Abe D, Sakaida E, Shimizu N, Yokote K, Iseki T, Nakaseko C. Successful treatment of sinusoidal obstructive syndrome/ hepatic veno-occlusive disease after unrelated bone marrow transplantation with recombinant soluble thrombomodulin. Am J Hematol. 2011; 86(10): 886-888. PMID:21818767
  14. Muto T, Takeuchi M, Kawaguchi T, Tanaka S, Tsukamoto S, Sakai S, Takeda Y, Abe D, Ohwada C, Sakaida E, Shimizu N, Yokote K, Iseki T, Nakaseko C. Low-dose trimethoprim-sulfamethoxazole for Pneumocystis jiroveci pneumonia prophylaxis after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2011; 46(12): 1573-1575. PMID: 21243025
  15. Kawaguchi T, Tsukamoto S, Ohwada C, Takeuchi M, Muto T, Tanaka S, Sakai S, Takeda Y, Abe D, Sakaida E, Shimizu N, Yokote K, Iseki T, Imadome K, Nakaseko C. Successful treatment with rituximab and donor lymphocyte infusions for fulminant EBV-associated lymphoproliferative disorder that developed 14 years after unrelated BMT. Bone Marrow Transplant. 2011; 46(12): 1583-1585. PMID: 21278799

 

和文論文

  1. 中世古知昭，竹内仁. ダサチニブによるPh陽性急性リンパ性白血病治療の可能性. Trends in Hematological Malignancies. 2011; 3(2): 106-109
  2. 中世古知昭. 原発性アミロイドーシスとPOEMS症候群に対する治療. 臨床血液. 2011; 52(10): 1496-1506.
  3. 塚本祥吉，中世古知昭.　EGFRシグナル伝達阻害物質によるG-CSF誘導性造血幹細胞総員の増強　血液内科 2011; 63(5): 580-585
  4. 千葉文子，小松悌介，米盛葉子，大出貴士，阿部大二郎，生坂政臣，中世古知昭，太田聡，中谷行雄　悪性リンパ腫の化学療法中に急性呼吸循環不全をきたして死亡した非外傷性肺脂肪塞栓症の一剖検例. 病理と臨床 2011; 29(6): 627-634
  5. 中世古知昭　多発性骨髄腫に対する造血幹細胞移植療法　血液内科　2011; 62(3): 291-300
  6. 中世古知昭.　血液疾患患者に対する薬物投与時の注意. 特集：一般内科医がみる血液疾患～血液専門医との効率的な連携のために　Medicina, 2011; 48(10): 1804-1808
  7. 中世古知昭．白血病治療におけるダサチニブのすべて ダサチニブの臨床応用と今後の展望：移植に対する処方経験．　監修：直江知樹，メディカルレビュー社，東京，2011, p70-71（単行本）
  8. 堺田恵美子，中世古知昭．　健康なからだ図鑑：リンパ　ひまわり倶楽部 2011; 6:22-25
  9. 阿部大二郎，中世古知昭．多発性骨髄腫に対する造血幹細胞移植. 特集　多発性骨髄腫の新時代を迎えて－診断と治療に吹き込む「新しい風」　内科 2011; 108(2): 247-251
  10. 武内正博，井関徹　末梢血幹細胞採取と成分採血－フェレーシスの理解と実践－　G-CSFの作用機序．　医薬ジャーナル社, 2011 p35-43（単行本）
  11. 阿部大二郎，中世古知昭．特発性血小板減少性紫斑病．特集：内科疾患インストラクションガイド　何をどう説明するか Medicina 2011; 48(11): 422-425
  12. 堺田恵美子, 滝口裕一. インフォームドコンセントのための図説シリーズ　肺癌　2011年版